Vutrisiran, a Gene-Silencing Drug, Demonstrates Significant Reductions in Mortality and Cardiovascular Events in Patients with Transthyretin-Mediated Amyloidosis Cardiomyopathy
Vutrisiran, a gene-silencing drug, led to impressive reductions in all-cause death and recurrent cardiovascular events in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), suggesting a new treatment option for this fatal disease.